Chronic Lung Diseases, COPD, Pulmonary Fibrosis
Conditions
Keywords
Dyspnea, Written Disclosure Therapy, COPD, Pulmonary Fibrosis, Chronic Lung Diseases, Pulmonary Rehabilitation
Brief summary
The purpose of this study is to determine whether Written Disclosure Therapy (WDT) is of any benefit to patients with chronic lung diseases who are participating in pulmonary rehabilitation.
Detailed description
Chronic lung diseases are typically associated with impaired quality of life, stress, and anxiety. Written disclosure therapy (WDT) reduces stress in patients with a variety of chronic illnesses. We sought to determine if written disclosure therapy benefits patients with chronic lung diseases when it is added as a component to the pulmonary rehabilitation program.
Interventions
OTHERDisclosure Writing (Written Disclosure Therapy)
Patients write about a stressful life experience
OTHERNeutral (Sham) Writing
Patients write about neutral subjects
Sponsors
Stony Wold-Herbert Fund, Inc.
Winthrop University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of COPD or Pulmonary Fibrosis * First time participants in Pulmonary Rehabilitation program
Exclusion criteria
* Dementia * Prior significant psychiatric illness * Inability to complete the questionnaires * Inability cooperate with spirometry * Inability or to participate in outpatient follow-up over the six-month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dyspnea and quality of life | Two-month and six-month time |
Secondary
| Measure | Time frame |
|---|---|
| Six-minute walk distance | Two-month and six-month time |
| Spirometry values (FEV1 and FVC) | Two-month and six-month time |
Outcome results
None listed